BioGaia and Ferring extend probiotic sales agreement

 
• By Simon Varcoe

BioGaia, a Swedish biotechnology company, has extended its agreement withFerring Pharmaceuticals over BioGaia's probiotics drops. The Swiss-based biopharmaceutical company has the rights to sell BioGaia's probiotic drops in Ireland and exclusive selling rights to the probiotic drops and tablets in Bahrain, Yemen, Qatar, Oman, Kuwait and the United Arab Emirates. BioGaia's products are based primarily on the lactic acid bacterium Lactobacillus reuteri, which the company claims has probiotic, health-enhancing effects. The two companies signed an initial agreement in March 2006, allowing Ferring to sell the drops in Spain, Portugal, Czech Republic and Hungary. The agreement was extended to Mexico, Brazil and Greece in August.

BioGaia, a Swedish biotechnology company, has extended its agreement withFerring Pharmaceuticals over BioGaia's probiotics drops. The Swiss-based biopharmaceutical company has the rights to sell BioGaia's probiotic drops in Ireland and exclusive selling rights to the probiotic drops and tablets in Bahrain, Yemen, Qatar, Oman, Kuwait and the United Arab Emirates. BioGaia's products are based primarily on the lactic acid bacterium Lactobacillus reuteri, which the company claims has probiotic, health-enhancing effects. The two companies signed an initial agreement in March 2006, allowing Ferring to sell the drops in Spain, Portugal, Czech Republic and Hungary. The agreement was extended to Mexico, Brazil and Greece in August.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Bitcoin Player Parataxis To Acquire Bridge Biotherapeutics After IPF Failure

 
• By Jung Won Shin

After the failure of its lead asset in a Phase II trial earlier this year, Korea's Bridge Biotherapeutics has accepted an acquisition offer from bitcoin group Parataxis.

Cidara’s Fortunes Improve Quickly With Non-Vaccine Flu-Prevention Data

 
• By Joseph Haas

Having recently abandoned the antifungal space, Cidara’s stock soared on Phase IIb data showing that its drug-Fc conjugate prevents seasonal flu at rates from 57%-76%.

Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 
• By Andrew McConaghie

As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.

More from Scrip

Merck & Co.’s Winrevair Positioned For Expansion On HYPERION Results

 
• By Jessica Merrill

The Phase III trial met the primary endpoint of time to clinical worsening in patients newly diagnosed with pulmonary arterial hypertension.

Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 
• By Andrew McConaghie

As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.